Targeted immune response for strong protection
We are developing modern vaccines using the latest recombinant technology to deliver effective protection against diseases. Our adenovector platform presents targeted proteins in the correct context for robust stimulation of the immune system.
Our platform technology has the potential to work with essentially any antigen. The vector is highly immunogenic and new vaccines can be produced rapidly at low cost and high yield.
Gentle administration for easy delivery
We are developing alternatives to the traditional needle, such as nasal and skin delivery methods. Many pathogens, including influenza and the bacterium that causes tetanus, enter the body through the nose or the skin. By vaccinating against these pathogens at the site of infection, our vaccines produce immunity where it is most needed.